Edgewise Therapeutics
Stock Forecast, Prediction & Price Target
Edgewise Therapeutics (EWTX) stock Price Target by analysts
$46.25
Potential upside: 251.57%
Edgewise Therapeutics price prediction
What is Edgewise Therapeutics stock analysts` prediction?
Edgewise Therapeutics stock forecast: Based on 4 Wall Street analysts` predicted price targets for Edgewise Therapeutics in the last 3 months, the avarage price target is $46.25, with a high forecast of $NaN. The average price target represents a 251.57% change from the last price of $13.16.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Edgewise Therapeutics stock Price Target by analysts
Full breakdown of analysts given Edgewise Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Srikripa Devarakonda Truist Financial | 0% 0/1 | 9 months ago | $50 280.08% upside | $31.57 | StreetInsider | Previous targets (0) |
Yasmeen Rahimi Piper Sandler | 0% 0/2 | 11 months ago | $51 287.68% upside | $30.46 | StreetInsider | Previous targets (1) |
Leonid Timashev RBC Capital | 0% 0/1 | 12 months ago | $42 219.27% upside | $29.5 | StreetInsider | Previous targets (0) |
Joseph Schwartz Leerink Partners | 0% 0/1 | 12 months ago | $42 219.27% upside | $29.5 | StreetInsider | Previous targets (0) |
Yasmeen Rahimi Piper Sandler | 0% 0/2 | about 1 year ago | $48 264.88% upside | $18.01 | StreetInsider | Previous targets (1) |
Edgewise Therapeutics Financial Estimates
Edgewise Therapeutics Revenue Estimates
Edgewise Therapeutics EBITDA Estimates
Edgewise Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $11.5M Low: $11.5M High: $11.5M avg. 0% | Avg: $105.76M Low: $105.76M High: $105.76M avg. 819.65% | Avg: $319.05M Low: $319.05M High: $319.05M avg. 201.67% |
Net Income
% change YoY
| $-42.13M N/A | $-15.39M 63.46% | $-100.16M -550.53% | Avg: $-177.95M Low: $-177.78M High: $-89.58M avg. -77.66% | Avg: $-183.90M Low: $-144.65M High: $-86.64M avg. -3.34% | Avg: $-111.51M Low: $-111.51M High: $-111.51M avg. 39.36% | Avg: $-12.90M Low: $-12.90M High: $-12.90M avg. 88.42% |
EBITDA
% change YoY
| $-43.21M N/A | $-22.07M 48.90% | $-112.80M -410.91% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$0.85 N/A | -$0.29 65.88% | -$1.57 -441.37% | Avg: -$1.99 Low: -$2.79 High: -$1.41 avg. -26.57% | Avg: -$1.72 Low: -$2.27 High: -$1.36 avg. 13.32% | Avg: -$1.75 Low: -$1.75 High: -$1.75 avg. -1.60% | Avg: -$0.2 Low: -$0.2 High: -$0.2 avg. 88.42% |
Operating Expenses
% change YoY
| $43.21M N/A | $22.07M -48.90% | $114.35M 417.94% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Edgewise Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 11.69% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -177.78M, average is -177.95M and high is -89.58M.
What is Edgewise Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 255.33% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is Edgewise Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 18.39% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$2.79, average is -$1.99 and high is $-1.40.
What is the best performing analyst?
In the last twelve months 4 analysts have been covering Edgewise Therapeutics stock. The most successful analyst is Srikripa Devarakonda.